HealthManagement
Promoting Management and Leadership

Advancing Hepatocellular Carcinoma Imaging



Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and one of the leading causes of cancer-related deaths globally. Early and accurate diagnosis remains a critical factor in improving patient outcomes. Current diagnostic modalities, such as contrast-enhanced CT and MRI, have known limitations in sensitivity and specificity, particularly when distinguishing early-stage or smaller lesions. These challenges necessitate innovative approaches to enhance diagnostic precision. A promising advancement is the development of a novel glypican-3 (GPC3) targeting agent, [68Ga]Ga-RAYZ-8009, which uses positron emission tomography/computed tomography (PET/CT) to enable high-contrast imaging of GPC3-positive lesions in HCC.

Glypican-3 as a Diagnostic Target

Glypican-3 (GPC3) is a cell surface heparan sulfate proteoglycan that plays a crucial role in cell growth regulation and has been identified as a promising biomarker for HCC. It is overexpressed in more than 70% of HCC cases, while its expression is nearly absent in normal adult liver tissues or cirrhotic liver conditions. This specific overexpression makes GPC3 a highly selective target for imaging and potential therapeutic interventions. Studies have demonstrated that GPC3 expression correlates with tumour aggressiveness and poor prognosis in patients with HCC. Thus, identifying GPC3-positive lesions early and accurately is critical for patient management and can significantly impact the course of treatment.

The [68Ga]Ga-RAYZ-8009 radiopharmaceutical is a peptide-based GPC3 ligand that binds specifically to GPC3 receptors. By labelling this ligand with Gallium-68 ([68Ga]), researchers can use PET/CT imaging to visualise and quantify the distribution of GPC3 expression in the liver and other tissues. Unlike conventional imaging modalities, [68Ga]Ga-RAYZ-8009 allows for more detailed and precise visualisation of HCC lesions, particularly in cases where traditional imaging might be ambiguous or inconclusive.

Enhanced Imaging and Clinical Implications

The [68Ga]Ga-RAYZ-8009 radiotracer has shown significant potential in improving the sensitivity and specificity of HCC diagnosis. In clinical studies involving patients with known or suspected HCC, the administration of [68Ga]Ga-RAYZ-8009 was followed by dynamic or static PET/CT scans. Results indicated that the radiotracer accumulated rapidly in GPC3-positive lesions, while uptake in normal liver tissue diminished significantly within 45 minutes after injection. This behaviour led to high tumour-to-liver uptake ratios, crucial for distinguishing malignant tissues from healthy or benign liver areas. Additionally, the tracer exhibited rapid clearance from other non-target organs, enhancing its diagnostic contrast.

In a study involving 24 patients with suspected or confirmed HCC, [68Ga]Ga-RAYZ-8009 successfully detected a total of 50 lesions, with some patients showing multiple lesions. Two patients with negative results did not develop HCC during the follow-up period, indicating the high specificity of the radiotracer. The uptake of [68Ga]Ga-RAYZ-8009 in these lesions was quantified using standardised uptake values (SUVs). The average maximum SUV (SUVmax) for detected lesions was approximately 19.6, with some lesions showing SUVmax values as high as 95.3, indicating strong radiotracer accumulation in high-GPC3-expressing lesions.

An important aspect of this novel imaging technique is its potential application in cases where traditional imaging methods are inconclusive. For instance, current guidelines for HCC diagnosis employ the Liver Imaging Reporting and Data System (LI-RADS) classification, which categorises liver lesions on a five-point scale ranging from “definitely benign” to “definitely HCC.” However, the sensitivity of LI-RADS for definitive diagnosis is limited, particularly for lesions that fall into intermediate categories (LI-RADS 3 or 4). By incorporating [68Ga]Ga-RAYZ-8009 PET/CT imaging, clinicians can potentially achieve a more definitive diagnosis in these ambiguous cases, thereby reducing diagnostic uncertainty and enabling more timely and targeted therapeutic interventions.

Safety, Efficacy and Future Directions

The safety profile of [68Ga]Ga-RAYZ-8009 has been favourable in early human studies. No adverse events were reported among the patients who underwent PET/CT scans with the radiotracer. Additionally, the radiochemical purity of the prepared [68Ga]Ga-RAYZ-8009 was consistently high, ensuring that the administered product was reliable and free from significant impurities. This consistent quality is essential for clinical applications, as it provides both patient safety and the accuracy of diagnostic results.

Beyond its diagnostic potential, the high tumour-specific uptake of [68Ga]Ga-RAYZ-8009 suggests it may have future therapeutic applications. By labelling the peptide with therapeutic radioisotopes, such as beta or alpha emitters, researchers could explore targeted radiotherapy options for treating GPC3-positive HCC. This dual diagnostic and therapeutic (theranostic) approach could provide a comprehensive solution for managing HCC, from early detection to targeted treatment.

Moreover, the utility of [68Ga]Ga-RAYZ-8009 is not limited to primary HCC lesions. The radiotracer demonstrated uptake in metastatic lesions, including those in the lungs and lymph nodes. This broader applicability is significant for comprehensive disease staging and is critical for planning treatment strategies and evaluating patient prognosis. In addition to staging, assessing metastatic involvement can also guide clinicians in determining the appropriate course of systemic therapy or local intervention.

Comparison with Existing Imaging Modalities

Currently, the gold standard for HCC diagnosis involves contrast-enhanced CT or MRI, with each modality having its advantages and limitations. While these imaging techniques provide anatomical details and help in identifying vascular patterns characteristic of HCC, they often struggle with specificity, particularly in cases involving cirrhotic liver backgrounds or small lesions. PET/CT with [68Ga]Ga-RAYZ-8009 offers a functional imaging alternative that goes beyond anatomy to visualise the molecular expression of GPC3. This added layer of information can help bridge the gap between anatomical and functional imaging, thereby improving overall diagnostic accuracy.

Another molecular imaging technique, 18F-FDG PET/CT, has been investigated for staging and prognosis in HCC. However, its utility is limited by the variable metabolic activity of HCC lesions. In contrast, [68Ga]Ga-RAYZ-8009 targets GPC3, which is more consistently expressed in HCC, offering a more reliable and tumour-specific imaging approach.

Introducing [68Ga]Ga-RAYZ-8009 represents a significant advancement in hepatocellular carcinoma imaging. By targeting GPC3, a key biomarker overexpressed in HCC, this radiotracer enables high-contrast, precise PET/CT imaging to improve the detection and diagnosis of HCC. Its ability to differentiate malignant from benign liver tissues, coupled with its rapid clearance from non-target organs, makes [68Ga]Ga-RAYZ-8009 a highly promising tool for HCC management.

Looking ahead, the potential applications of [68Ga]Ga-RAYZ-8009 extend beyond diagnostic imaging to include targeted radiotherapy, offering a dual diagnostic and therapeutic approach for GPC3-positive HCC. Further clinical studies are warranted to validate these findings and establish the radiotracer's role in routine clinical practice. If successful, [68Ga]Ga-RAYZ-8009 could revolutionise how clinicians diagnose, stage and treat HCC, ultimately improving patient outcomes and advancing the field of liver cancer management.

Source: **Journal of Nuclear Medicine**

Image Credit: **iStock**

Published on : Sun, 27 Oct 2024